EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Single-cell and multi-omics integration delineates the landscape of gene-wise intratumor heterogeneity and identifies prognostic biomarkers for immunotherapy in non-small cell lung cancer

Jianye Yuan, Zelin Weng, Zhenguo Li, Rui Chen, Chao Cheng, Weixiong Yang, Xiuying Xie, Chang Luo, Tao Wang, Shuishen Zhang, Zihui Tan

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04454-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Jianye Yuan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Sun Yat-Sen University First Affiliated Hospital, Guangzhou, Guangdong, China. yuanjy55@mail.sysu.edu.cn. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Biomarkers, Tumor. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Science and Technology Foundation of Guangdong Province, Guangdong Esophageal Cancer Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Gene-wise intratumor heterogeneity (ITH), defined as spatial variability in the expression of individual genes across tumor regions, remains incompletely characterized in non-small cell lung cancer (NSCLC). Identifying low-ITH genes as predictive biomarkers offers a promising strategy to enhance the reliability of immunotherapy outcome prediction. METHODS: We profiled gene-wise ITH using multi-region scRNA-seq data and a computational framework combining variance and clustering metrics. Prognostic low-ITH genes were screened via immunotherapy RNA-seq datasets and six machine learning algorithms to construct the LITHrisk score. Transcriptomic profiling and in vitro experiments elucidated the biological and functional relevance of key score components. RESULTS: The gene-wise ITH landscape in NSCLC was delineated, with several critical immune checkpoint genes, including PD-L1, LAG3, and TIM-3, being identified as low-ITH genes. A low-ITH-derived signature, the LITHrisk score (PD-L1, CDK11B, CXCL13, RPS4Y1, AKR1B10, CRLF1), effectively predicted immunotherapy prognosis and response in NSCLC and other cancers. Tumors with a low LITHrisk score were characterized by enrichment of immune response-related pathways and heightened infiltration of immune cells, such as T cells, B cells, and myeloid cells. Furthermore, we found that component genes of the score were linked to key tumor characteristics: AKR1B10 was associated with tumor immune interactions, functioning via SPP1 regulation to suppress anti-tumor immunity, while CRLF1 was implicated in promoting a fibroblast-enriched microenvironment and modulating tumor cell motility. CONCLUSION: Our study provides a practical transcriptome-based tool for advancing precision immunotherapy and nominates potential therapeutic targets for enhancing treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyBiomarkers, TumorSingle-Cell AnalysisHumansPrognosisMultiomicsGene Expression ProfilingGene Expression Regulation, NeoplasticGenetic Heterogeneity

Stichwörter der Autor:innen

Gene-wise intratumor heterogeneityImmunotherapyNon-small cell lung cancerPrognostic biomarkers

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Sun Yat-Sen University First Affiliated Hospital, Guangzhou, Guangdong, China. yuanjy55@mail.sysu.edu.cn.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
  • Department of Thoracic Surgery, Sun Yat-Sen University First Affiliated Hospital, Guangzhou, Guangdong, China.
  • Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
  • Guangdong Esophageal Cancer Institute, Guangzhou, Guangdong, China.

Förderung

  • Medical Science and Technology Foundation of Guangdong Province
  • Guangdong Esophageal Cancer Research Institute

Zitieren

APA

Yuan, J., Weng, Z., Li, Z., Chen, R., Cheng, C., Yang, W., Xie, X., Luo, C., Wang, T., Zhang, S., & Tan, Z. (2026). Single-cell and multi-omics integration delineates the landscape of gene-wise intratumor heterogeneity and identifies prognostic biomarkers for immunotherapy in non-small cell lung cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04454-4

Vancouver

Yuan J, Weng Z, Li Z, Chen R, Cheng C, Yang W, et al. Single-cell and multi-omics integration delineates the landscape of gene-wise intratumor heterogeneity and identifies prognostic biomarkers for immunotherapy in non-small cell lung cancer. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04454-4

BibTeX
@article{Yuan2026,
  author = {Yuan, Jianye and Weng, Zelin and Li, Zhenguo and Chen, Rui and Cheng, Chao and Yang, Weixiong and Xie, Xiuying and Luo, Chang and Wang, Tao and Zhang, Shuishen and Tan, Zihui},
  title = {Single-cell and multi-omics integration delineates the landscape of gene-wise intratumor heterogeneity and identifies prognostic biomarkers for immunotherapy in non-small cell lung cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04454-4}
}
Kostenlos starten →